In recent years, research has shown promising correlations between specific blood biomarkers and Alzheimer’s disease pathology in the brain, particularly regarding the burden of misfolded amyloid-β. This has spurred the development of blood tests for Alzheimer’s disease, aiming to streamline the testing process and avoid costly imaging or invasive procedures. Detecting early signs of Alzheimer’s risk opens up avenues for intervention, from lifestyle changes to innovative therapies targeting amyloid-β buildup in the brain.
Accurate detection of Alzheimer’s disease pathology remains a crucial challenge in advancing clinical research. Screening methods that can pinpoint high-risk individuals for research trials would greatly enhance the efficiency of clinical studies. The accumulation of amyloid beta plaques and tau protein tangles in the brain characterizes Alzheimer’s disease, prompting the exploration of blood-based biomarkers for early detection. Studies have identified promising candidates like Aβ40, Aβ42, and tau proteins for this purpose.
The Bio-Hermes Study aimed to assess the effectiveness of various blood-based and digital biomarkers in detecting brain amyloid in participants similar to those in clinical trials. Results revealed that the Aβ42/Aβ40 ratio, p-tau181, and p-tau217 show promise in predicting brain amyloid positivity in a clinical trial-ready population.
Link: https://doi.org/10.1002/alz.13722
